CDC Expedites Release of Thousands of RSV Shots for Infants Amid Shortage

The US Centers for Disease Control and Prevention (CDC) has announced the expedited distribution of over 77,000 additional doses of nirsevimab, an RSV immunization for infants, to address the ongoing shortage. The monoclonal antibody, marketed as Beyfortus, helps protect infants from severe respiratory syncytial virus (RSV) infections, which are a leading cause of hospitalization in infants. The CDC and FDA will work closely with manufacturers to ensure the availability of more doses through the end of the year and early next year. The shortage has raised concerns among public health officials as RSV cases rise during the winter season. Challenges include limited access to the vaccine in birthing hospitals and the high cost of the immunization. Efforts are underway to address these issues and improve access in future seasons.